ROCKET PHARMACEUTICALS, INC. - Common Stock, $0.01 par value per share (RCKT) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2018 to Q4 2025

Type / Class
Equity / Common Stock, $0.01 par value per share
Symbol
RCKT on Nasdaq
Shares outstanding
107,228,372
Price per share
$3.51
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
96,588,463
Total reported value
$314,789,901
% of total 13F portfolios
0%
Share change
+1,637,373
Value change
+$10,419,402
Number of holders
171
Price from insider filings
$3.51
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of ROCKET PHARMACEUTICALS, INC. - Common Stock, $0.01 par value per share (RCKT) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
MAVERICK CAPITAL LTD 7.8% +52% $28,018,774 +$9,435,737 8,363,813 +51% Maverick Capital, Ltd. 30 Jun 2025
WELLINGTON MANAGEMENT GROUP LLP 0.9% -83% $7,895,181 -$48,317,346 1,004,476 -86% Wellington Management Group LLP 30 May 2025

As of 30 Sep 2025, 171 institutional investors reported holding 96,588,463 shares of ROCKET PHARMACEUTICALS, INC. - Common Stock, $0.01 par value per share (RCKT). This represents 90% of the company’s total 107,228,372 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of ROCKET PHARMACEUTICALS, INC. - Common Stock, $0.01 par value per share (RCKT) together control 76% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
RTW INVESTMENTS, LP 16% 17,687,772 0% 0.71% $57,662,137
MAVERICK CAPITAL LTD 7.9% 8,468,344 +1.2% 0.37% $27,606,801
BlackRock, Inc. 6.6% 7,114,371 -4.2% 0% $23,192,850
VANGUARD GROUP INC 6.4% 6,892,204 +13% 0% $22,468,585
MPM BIOIMPACT LLC 3.6% 3,903,381 +0.01% 2.1% $12,725,022
SUVRETTA CAPITAL MANAGEMENT, LLC 3.6% 3,843,333 -7.2% 0.38% $12,529,266
MORGAN STANLEY 3.4% 3,647,039 +15% 0% $11,889,347
MILLENNIUM MANAGEMENT LLC 3.3% 3,570,391 +52% 0.01% $11,639,475
Monaco Asset Management SAM 2.7% 2,892,261 +539% 3.5% $9,428,771
Newtyn Management, LLC 2.3% 2,502,863 +25% 1% $8,159,333
D. E. Shaw & Co., Inc. 2% 2,189,750 +121% 0.01% $7,138,585
JPMORGAN CHASE & CO 2% 2,097,033 +74% 0% $6,836,329
GEODE CAPITAL MANAGEMENT, LLC 1.8% 1,914,554 -5.7% 0% $6,242,766
TWO SIGMA ADVISERS, LP 1.7% 1,795,751 +20% 0.01% $5,854,148
STATE STREET CORP 1.6% 1,745,310 -10% 0% $5,689,711
CITADEL ADVISORS LLC 1.6% 1,670,927 +971% 0% $5,447,222
TWO SIGMA INVESTMENTS, LP 1.5% 1,609,682 -6.7% 0.01% $5,247,563
Balyasny Asset Management L.P. 1.2% 1,313,737 +897% 0.01% $4,282,783
GOLDMAN SACHS GROUP INC 1.2% 1,271,093 -19% 0% $4,143,763
Prosight Management, LP 1.2% 1,267,965 -20% 0.99% $4,133,566
PRICE T ROWE ASSOCIATES INC /MD/ 0.99% 1,061,295 -3.5% 0% $3,461,000
Qube Research & Technologies Ltd 0.95% 1,014,358 -34% 0% $3,306,807
AQR CAPITAL MANAGEMENT LLC 0.81% 873,247 +12% 0% $2,846,787
TANG CAPITAL MANAGEMENT LLC 0.79% 850,000 0% 0.11% $2,771,000
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.69% 744,074 +21% 0% $2,425,681

Institutional Holders of ROCKET PHARMACEUTICALS, INC. - Common Stock, $0.01 par value per share (RCKT) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 459,455 $1,613,479 -$62,724 $3.51 11
2025 Q3 96,588,463 $314,789,901 +$10,419,402 $3.26 171
2025 Q2 94,974,795 $232,855,173 -$147,581,505 $2.45 194
2025 Q1 107,749,040 $722,024,527 -$52,696,397 $6.67 233
2024 Q4 109,631,659 $1,377,351,827 +$164,833,266 $12.57 222
2024 Q3 92,544,368 $1,706,444,337 +$15,875,062 $18.47 189
2024 Q2 91,223,637 $1,963,433,591 -$31,837,475 $21.53 179
2024 Q1 91,974,687 $2,477,726,425 +$110,873,444 $26.94 187
2023 Q4 41,184 $1,249,815 -$747,548 $30.44 2
2023 Q3 89,141,004 $1,826,437,823 +$245,951,490 $20.49 172
2023 Q2 76,078,558 $1,511,714,506 -$36,051,312 $19.87 160
2023 Q1 78,156,567 $1,338,551,481 +$44,234,621 $17.13 158
2022 Q4 75,852,442 $1,485,072,775 +$146,463,386 $19.57 163
2022 Q3 68,958,538 $1,099,282,174 +$65,749,690 $15.96 154
2022 Q2 64,497,046 $886,774,522 +$4,027,519 $13.76 138
2022 Q1 62,501,353 $990,923,106 +$10,056,136 $15.86 138
2021 Q4 63,072,367 $1,377,378,826 +$9,180,537 $21.83 137
2021 Q3 61,537,276 $1,836,566,305 -$26,016,240 $29.89 140
2021 Q2 61,689,267 $2,731,298,703 -$54,402,561 $44.29 143
2021 Q1 61,878,560 $2,746,621,087 -$19,110,347 $44.37 169
2020 Q4 61,903,041 $3,394,932,061 +$434,519,153 $54.84 169
2020 Q3 55,130,741 $1,260,335,245 +$22,868,135 $22.86 121
2020 Q2 53,170,068 $1,112,863,207 +$14,383,064 $20.93 112
2020 Q1 51,989,631 $725,255,762 +$12,378,020 $13.95 99
2019 Q4 51,106,762 $1,163,184,498 +$87,930,325 $22.76 115
2019 Q3 43,322,231 $503,999,335 -$33,097,941 $11.65 88
2019 Q2 47,006,757 $705,059,854 +$95,676,125 $15.00 93
2019 Q1 39,892,418 $698,663,351 +$16,498,634 $17.54 78
2018 Q4 38,562,500 $569,600,055 +$71,211,807 $14.82 82
2018 Q3 33,793,206 $831,986,120 +$69,946,609 $24.62 80
2018 Q2 31,064,522 $605,382,076 +$63,874,925 $19.63 75
2018 Q1 27,975,561 $502,084,019 +$502,084,111 $18.75 55